Simulations Plus (SLP) announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration FDA to use physiologically based pharmacokinetic PBPK approaches in GastroPlus ...
Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Physiologically based pharmacokinetics (PBPK), as the name implies, is a special branch of pharmacokinetics where physiology and anatomy of the animal or human body, as well as the biochemistry of the ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...
PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc., the global leader in biosimulation, today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results